linrodostat: Clinical Trials

12 completed, 1 active not recruiting, 1 terminated. 14 Phase 1, 4 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	14	Completed 12, Active not recruiting 1, Terminated 1
Phase 2	4	Completed 3, Terminated 1

Follow linrodostat: new trials by email Literature Review of linrodostat trials Research Report on linrodostat

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma IDO1 Inhibitor BMS-986205 25mg, Nivolumab, Radiation Therapy - Glioblastoma	Phase 1	Active not recruiting	Northwestern University	18	2019-08-13	2025-06-29
A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants BMS-986205, omeprazole - Healthy	Phase 1	Completed	Bristol-Myers Squibb	16	2019-05-08	2019-09-23
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors BMS-986205, Nivolumab - Advanced Cancer	Phase 1 / Phase 2	Completed	Bristol-Myers Squibb	12	2018-12-31	2022-02-28
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer IDO1 Inhibitor BMS-986205, Nivolumab - Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8	Phase 1 / Phase 2	Terminated	Edward Kim	8	2018-10-16	2026-07-29
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Relatlimab, Nivolumab, BMS-986205 - Advanced Cancer	Phase 1 / Phase 2	Completed	Bristol-Myers Squibb	229	2018-05-30	2026-04-06
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment Nivolumab, Relatlimab, Cabiralizumab - Advanced Cancer	Phase 1	Completed	Bristol-Myers Squibb	20	2018-05-07	2022-09-26
A Study to Evaluate the Bioavailability of BMS-986205 BMS-986205 - Healthy Participants	Phase 1	Completed	Bristol-Myers Squibb	7	2018-01-04	2018-06-28
A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet BMS-986205 reference tablet, BMS-986205 tablet with free base - Healthy Volunteers	Phase 1	Completed	Bristol-Myers Squibb	16	2017-12-21	2018-02-28
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects BMS-986205, Itraconazole, Rifampin - Malignancies Multiple	Phase 1	Completed	Bristol-Myers Squibb	53	2017-11-22	2018-02-28
A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet BMS-986205 - Healthy Volunteers	Phase 1	Completed	Bristol-Myers Squibb	40	2017-11-09	2018-02-23
An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants BMS-986205 - Healthy Volunteers	Phase 1	Completed	Bristol-Myers Squibb	32	2017-10-09	2018-01-19
Pharmacokinetics and Metabolism Study in Healthy Male Participants BMS-986205 - Cancer	Phase 1	Completed	Bristol-Myers Squibb	9	2017-07-19	2017-11-06
A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors BMS-986205, Nivolumab - Advanced Cancer	Phase 1	Completed	Bristol-Myers Squibb	11	2017-06-23	2019-04-01
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread BMS-986205, Nivolumab, Ipilimumab - Advanced Cancer, Melanoma	Phase 1 / Phase 2	Completed	Bristol-Myers Squibb	627	2016-04-14	2023-08-28

Conditions studied

Neoplasms (2)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Glioblastoma (1)  ·  Melanoma (1)

Sponsors

Bristol-Myers Squibb (12)  ·  Edward Kim (1)  ·  Northwestern University (1)

Countries

United States (11)  ·  Australia (2)  ·  France (2)  ·  Italy (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Canada (1)  ·  China (1)  ·  Finland (1)  ·  Germany (1)  ·  Japan (1)  ·  Norway (1)  ·  Poland (1)  ·  Sweden (1)  ·  Switzerland (1)

Top investigators

Antonia Davidson, MD (1)  ·  Edward Kim, MD, PhD (1)  ·  Rimas V Lukas, MD (1)

Results publications

PMID 40389374, PMID 41041559, PMID 42189896

NIH funding

2015 (1), 2017 (1), 2018 (1), P30CA060553 (1), P30CA093373 (1), P50CA221747 (1)